Dr. Huober on Selection Criteria for Adjuvant Systemic Therapy for Breast Cancer
Jens Huober, MD
Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer
Not every patient should receive extended adjuvant endocrine treatment because it can be an overtreatment for many patients, explains Huober.
The best selection criteria currently available is the initial tumor size, particularly if the patient has node-positive or node-negative disease. Other biological adverse prognostic features, such as high-proliferation index or T3 tumors, are also potential selection criteria, states Huober.